Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
OLMA | US
-0.45
-3.73%
Healthcare
Biotechnology
30/06/2024
04/10/2024
11.60
11.60
11.85
11.46
Olema Pharmaceuticals Inc. a clinical-stage biopharmaceutical company focuses on the discovery development and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250 an estrogen receptor (ER) antagonist and a selective ER degrader which is in Phase 1/2 clinical trial for the treatment of recurrent locally advanced or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib ribociclib and alpelisib in Phase 1b/2 clinical trial for the treatment of recurrent locally advanced or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera Inc. and changed its name to Olema Pharmaceuticals Inc. in March 2009. Olema Pharmaceuticals Inc. was incorporated in 2006 and is headquartered in San Francisco California.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
34.9%1 month
54.9%3 months
67.1%6 months
74.8%-
-
3.07
0.01
0.01
-3.33
-
-
-122.27M
664.29M
664.29M
-
-
-
-
-56.40
18.43
26.77
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
2.47
Range1M
3.02
Range3M
6.33
Rel. volume
0.37
Price X volume
2.35M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Arbutus Biopharma Corporation | ABUS | Biotechnology | 3.84 | 724.92M | -1.54% | n/a | 6.09% |
Erasca Inc. Common Stock | ERAS | Biotechnology | 2.54 | 717.56M | 0.79% | n/a | 11.96% |
Pliant Therapeutics Inc. | PLRX | Biotechnology | 11.53 | 701.04M | 5.68% | n/a | 15.34% |
Terns Pharmaceuticals Inc. | TERN | Biotechnology | 8.27 | 698.29M | 0.85% | n/a | 0.11% |
Mineralys Therapeutics Inc. | MLYS | Biotechnology | 13.88 | 690.21M | 8.44% | n/a | 0.00% |
CureVac N.V | CVAC | Biotechnology | 3.02 | 679.69M | 0.67% | n/a | 10.37% |
Avid Bioservices Inc | CDMO | Biotechnology | 10.63 | 678.14M | -1.02% | n/a | 353.77% |
ORIC Pharmaceuticals Inc | ORIC | Biotechnology | 9.61 | 677.91M | -1.84% | n/a | 0.92% |
Mereo BioPharma Group plc | MREO | Biotechnology | 4.4 | 676.95M | 2.56% | n/a | 7.83% |
ATXS | ATXS | Biotechnology | 11.87 | 669.77M | 2.06% | n/a | 1.67% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Ennis Inc | EBF | Building Products & Equipment | 24.31 | 631.67M | 2.36% | 15.15 | 2.42% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.25 | 502.94M | -0.19% | n/a | 174.23% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -3.33 | 0.76 | Cheaper |
Ent. to Revenue | - | 3,674.48 | - |
PE Ratio | - | 38.01 | - |
Price to Book | 3.07 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 67.05 | 74.67 | Par |
Debt to Equity | 0.01 | -1.82 | Expensive |
Debt to Assets | 0.01 | 0.26 | Cheaper |
Market Cap | 664.29M | 3.73B | Emerging |